KIMBERLY BROOKE KOENIG

TitleAssociate Professor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240. PMID: 33140515.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 Mar 01; 27(5):1247-1255. PMID: 33115815.
      Citations:    Fields:    
    3. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351. PMID: 30610588.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    4. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400.
      Citations: 3     
    5. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
    6. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77. PMID: 27287781.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    7. Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res. 2016 Dec 01; 22(23):5706-5712. PMID: 27166393.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    8. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2015 Nov; 1(8):1087-95. PMID: 26291768.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    9. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. PMID: 25878190.
      Citations: 26     Fields:    Translation:Humans
    10. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31. PMID: 25913905.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    11. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8. PMID: 24677057.
      Citations: 19     Fields:    Translation:Humans
    12. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    13. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11. PMID: 24562447.
      Citations: 37     Fields:    Translation:Humans
    14. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013 Jan; 71(1):63-72. PMID: 23053261.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    15. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34. PMID: 22291085.
      Citations: 67     Fields:    Translation:Humans
    16. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. PMID: 21482991.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    17. Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15:325-331.
    18. TBCRC-010. Clinical Cancer Research. 22:5706-5712.
    19. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    20. Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation. Journal of Breast Cancer. 17:287-290.
    KOENIG's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (102)
    Explore
    _
    Co-Authors (50)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _